Biogenic silver nanoparticles in the treatment of experimental pythiosis Bio-AgNP in pythiosis therapy.

The article discusses a study that examines effectiveness of biogenic silver nanoparticles for treating an experimental form of pythiosis, a disease with known resistance to existing treatments. The researchers used rabbits for testing and discovered that silver nanoparticles could potentially serve as a valuable addition to integrative medicine and the treatment regimen for pythiosis.

What is Pythiosis and Biogenic Silver Nanoparticles?

• Pythiosis is a severe and rapidly progressing disease that can be fatal. It primarily affects mammals, including humans and particularly horses, and is notoriously resistant to most current therapeutic protocols. These traits make it a focal point for researchers looking into new forms of treatment.
• Biogenic silver nanoparticles (bio-AgNP) are tiny particles of silver, produced by biological entities, that have shown promising results in antibacterial, anticancer, anti-inflammatory, and antimicrobial applications.

Research Design and Methodology

• The study utilized nine 90-day-old New Zealand female rabbits, which were divided into three groups for treatment.
• The first group served as the control group and was treated topically with a nonionized gel formulation and sterile distilled water, administered to the lesion every two days.
• The second group received a topical gel containing bio-AgNP daily; meanwhile, the third group was treated with an aqueous solution of bio-AgNP, applied directly to the lesion also every two days.
• The rabbits were treated for a total period of 45 days, and the size of subcutaneous lesions was measured every 5 days to evaluate the effectiveness of the treatments.

Findings

• Results indicated that both groups treated with bio-AgNP (groups 2 and 3) demonstrated significant reduction in their lesion areas and the amount of hyphae in the lesions compared to the control group.
• No significant difference was noted between the two experimental groups, suggesting that the route of application did not impact the effectiveness of the nanoparticles. This highlights the versatility of bio-AgNP as a potential treatment method.
• Additionally, one test subject from the group treated with topical bio-AgNP reached a clinical cure at day 35 of the treatment, lending further credence to the potential effectiveness of this approach.

Conclusion

• This study represents pioneering research into the potential therapeutic applications of nanocomposites in treating experimental pythiosis.
• The findings suggest that bio-AgNP can serve as powerful adjuncts to integrative medicine and are worth considering as potential options for inclusion in the treatment protocols for pythiosis.